Trials / Unknown
UnknownNCT04305392
Pharmacokinetics, Pharmacodynamics and Safety of SHR4640 in Patients With Hepatic Impairment
Pharmacokinetics, Pharmacodynamics and Safety of SHR4640 in Patients With Hepatic Impairment (Multicenter, Single Dose, Parallel, Open)
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
Study to evaluate pharmacokinetics, pharmacodynamics and safety of SHR4640 in patients with mild, moderate hepatic impairment and normal liver function in phase I clinical study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR4640 | orally SHR4640 |
Timeline
- Start date
- 2020-08-04
- Primary completion
- 2022-12-01
- Completion
- 2022-12-01
- First posted
- 2020-03-12
- Last updated
- 2022-08-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04305392. Inclusion in this directory is not an endorsement.